8-K: Myomo Appoints Joseph M. Manko Jr. to Board of Directors

Myomo, Inc. announced the appointment of Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026, bringing extensive experience in investment banking and corporate governance.

Summary

• Myomo, Inc. has appointed Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026.
• Mr. Manko will serve as a Class I director until the 2027 annual meeting of shareholders.
• He is the Senior Principal of Horton Capital Management LLC, a significant shareholder in Myomo.
• Mr. Manko brings over 25 years of experience in investment banking, private equity, asset management, and corporate strategy.
• His background includes roles at BZ Fund Management, Deutsche Bank, Merrill Lynch, and Skadden, Arps, Slate, Meagher & Flom LLP.
• He currently serves on the boards of Safeguard Scientifics, Inc. and Koru Medical Systems, Inc.
• Mr. Manko's appointment is intended to support the company's growth strategy and drive long-term shareholder value.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the addition of an experienced director with a significant shareholder stake, expected to contribute to strategic growth and shareholder value.

Positives

• Appointment of a director with significant experience in investment banking, private equity, and corporate governance.
• Mr. Manko is a significant shareholder, indicating alignment with shareholder interests.
• His expertise is expected to support Myomo's growth strategy and drive long-term shareholder value.
• The appointment adds a seventh director to the board, potentially enhancing oversight.
• Mr. Manko's background includes advising companies in the med-tech and bio-pharmaceutical industries, relevant to Myomo's sector.

Risks

• The filing does not explicitly mention any risks associated with this appointment.
• Potential for director compensation to impact company expenses, though details are provided for existing directors.

Future Outlook

Mr. Manko looks forward to working with management and fellow directors to support the company's growth strategy, expand patient access, and drive long-term value for shareholders.

Management Comments

• "We are pleased to welcome Joe to our Board of Directors. Through The Horton Fund, Joe has long been a steadfast investor and supporter for years. He brings strong capital markets, strategic planning, and corporate governance experience to our Board, with a history of driving shareholder value in growth businesses. We are pleased to add his perspective as we execute on our Success Pillars for 2026 and beyond."
• "I am excited to join the Myomo Board of Directors at such an important time in the Company's development. Myomo has built an innovative technology platform that is making a meaningful impact on patients lives, while addressing a significant unmet need. I look forward to working closely with management and my fellow directors to help support the Company's growth strategy, expand patient access, and drive long-term value for shareholders."

Industry Context

StockSavvy.ai notes that the appointment of experienced financial and governance professionals to the board is a common strategy for companies in the competitive wearable medical robotics sector aiming to strengthen strategic direction and investor confidence.

Management Changes

Corporate Governance

Related Party Transactions

• Mr. Manko is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.
• There are no arrangements or understandings between Mr. Manko and any other persons pursuant to which he was selected as a director.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value and improved strategic direction due to Mr. Manko's expertise and significant shareholding.
• Management: Will work with a new director bringing extensive financial and strategic experience.
• Board of Directors: Enhanced expertise and potentially improved decision-making with the addition of Mr. Manko.

Next Steps

• Mr. Manko will serve as a Class I director until the 2027 annual meeting of shareholders.
• He will be compensated in the same manner as other non-employee directors for his service on the Board beginning after the 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

Myomo, Board of Directors, Joseph M. Manko Jr., Corporate Governance, Investment Banking, Wearable Medical Robotics, Director Appointment, Shareholder Value